Hualan Ankang Biotechnology

Hualan Ankang Biotechnology Co., Ltd. (formerly Hualan Genetic Engineering Co., Ltd.) is a Chinese biotechnology and CDMO company based in Xinxiang, Henan Province. The company is a participating subsidiary of Hualan Biological Engineering Inc. and focuses on the research, development, and commercialization of innovative drugs and biosimilars, particularly monoclonal antibodies. Its pipeline includes several biosimilars targeting major pathways such as VEGF (bevacizumab biosimilar, approved), TNF-alpha (adalimumab biosimilar, NDA filed), CD20 (rituximab biosimilar), RANKL (denosumab biosimilar, NDA filed), and PD-1 (pembrolizumab biosimilar, Phase 1/2). In addition to its therapeutic pipeline, Hualan Ankang operates as a CDMO, providing services ranging from cell line development and process optimization to commercial-scale drug substance and drug product manufacturing.